Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic and nongenetic factors influencing the response to clopidogrel.

Journal of cardiovascular medicine (Hagerstown, Md.) - 1 Dec 2013

Notarangelo Maria F, Bontardelli Federico, Merlini Piera Angelica

Abstract excerpt

The antiplatelet drug clopidogrel is a commonly prescribed therapy in patients with acute coronary syndrome. However, its clinical efficacy is hampered by a wide inter-patient response variability, with over 30% of patients treated with this drug experiencing an inadequate antiplatelet response. There are growing evidences that clopidogrel response variability is associated with cytochrome P450 (CYP) enzyme...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Coronary Syndrome
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clopidogrel

Share to Cytochrome P-450 CYP2C19

Share to Drug Interactions

Share to Platelet Aggregation Inhibitors

Share to Proton Pump Inhibitors

Share to Ticlopidine

Source

Identifiers

PMID: 24378836
DOI: 10.2459/JCM.0b013e328364bb04

Genes

ABCB1
PON1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic and nongenetic factors influencing the response to clopidogrel.PMID 24378836Read ↗

The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19.Semantic proximity Read ↗

Recent advances in the pharmacogenetics of clopidogrel.Semantic proximity Read ↗

CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).Semantic proximity Read ↗

Genetic determinants of on-clopidogrel high platelet reactivity.Semantic proximity Read ↗

Genetic causes of clopidogrel nonresponsiveness: which ones really count?Semantic proximity Read ↗

The CYP2C19*2 and CYP2C19*17 Polymorphisms play a Vital Role in Clopidogrel Responsiveness after Percutaneous Coronary Intervention: A Pharmacogenomics Study.Semantic proximity Read ↗

Pharmacogenetics of clopidogrel.Semantic proximity Read ↗

Clopidogrel PharmacogeneticsSemantic proximity Read ↗

Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease.Semantic proximity Read ↗

Clopidogrel and genetic testing: is it necessary for everyone?Semantic proximity Read ↗

Pharmacogenomics of clopidogrel: evidence and perspectives.Semantic proximity Read ↗

Genotyping genetic variants of CYP2C19 for precision antiplatelet dosing: state of the art and future perspectives.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.